Defunct Company
Total Trials
19
As Lead Sponsor
18
As Collaborator
1
Total Enrollment
5,917
NCT01171898
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jul 26, 2010
Completion: Jul 22, 2025
NCT01792687
Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate
Phase: Phase 1
Start: Feb 5, 2013
Completion: Feb 13, 2024
NCT01790126
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Phase: Phase 2
Start: Mar 4, 2013
Completion: Mar 1, 2019
NCT01822041
14C-ARN-509 Microtracer Label AME and Absolute BA Study
Start: Mar 31, 2013
Completion: Jun 30, 2013
NCT01946204
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Phase: Phase 3
Start: Oct 14, 2013
Completion: Dec 31, 2027
NCT02031666
A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants
Start: Dec 31, 2013
Completion: Apr 30, 2014
NCT02106507
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Role: Collaborator
Start: Apr 30, 2014
Completion: Jun 28, 2021
NCT02160756
Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants
Start: Jun 30, 2014
Completion: Nov 30, 2014
NCT02123758
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Start: Jul 9, 2014
NCT02230033
Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927
Start: Sep 30, 2014
Completion: Dec 31, 2014
NCT02257736
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Start: Nov 26, 2014
NCT02524717
A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function
Start: Aug 13, 2015
Completion: Feb 9, 2017
NCT02531516
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Start: Nov 19, 2015
Completion: Dec 29, 2028
NCT02489318
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
Start: Nov 27, 2015
NCT02578797
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
Start: Dec 18, 2015
Completion: Oct 13, 2022
NCT02592317
A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer
Start: Feb 12, 2016
Completion: Oct 9, 2024
NCT05903118
A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
Start: Jan 8, 2022
Completion: Jul 19, 2023
NCT05897190
Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster
Start: May 16, 2022
Completion: May 12, 2023